Levodopa-induced motor fluctuations (MF) is a disabling complication of Parkinson's disease (PD) and is usually refractory to conventional treatment. Apomorphine, a dopamine agonist with affinity for both D1 and D2 receptors, has been emerged as an useful alternative in the management of MF of PD. The frequency of nausea and vomiting prevented its use in the past, but the simultaneous administration of domperidone has proved to be able to control these side effects. Although apomorphine has been successfully used to control levodopa-induced MF in other countries, it has not been considered in the management of PD in Brazil. We report here our initial experience with subcutaneous injections of apomorphine combined to oral domperidone. We adm...
Continuous infusion of levodopa or apomorphine provide constant dopaminergic stimulations are good a...
The effectiveness of oral levodopa in complex Parkinson's disease (PD) is limited by its short half-...
OBJECTIVES: Despite the recent introduction of new peroral drugs as well as neurosurgical methods fo...
Apomorphine is a potent, nonselective, direct-acting dopamine-receptor agonist. Given subcutaneously...
The clinical utility of long-term oral levodopa therapy in Parkinson disease (PD) is often limited b...
ABSTRACT Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and cont...
Extensive published evidence supports the use of subcutaneously-administered apomorphine as an effec...
BackgroundSubcutaneous apomorphine infusion is a clinically established therapy for patients with Pa...
Background Subcutaneous apomorphine infusion is a clinically established therapy for patients with P...
The current pharmacotherapy of Parkinson's disease (PD) is primarily based on two classes of drugs: ...
Five patients with idiopathic Parkinson's disease with severe response fluctuations were selected fo...
Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications du...
Apomorphine in combination with a peripheral dopamine receptor blocker (domperidone) was administere...
Continuous infusion of levodopa or apomorphine provide constant dopaminergic stimulations are good a...
The effectiveness of oral levodopa in complex Parkinson's disease (PD) is limited by its short half-...
OBJECTIVES: Despite the recent introduction of new peroral drugs as well as neurosurgical methods fo...
Apomorphine is a potent, nonselective, direct-acting dopamine-receptor agonist. Given subcutaneously...
The clinical utility of long-term oral levodopa therapy in Parkinson disease (PD) is often limited b...
ABSTRACT Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and cont...
Extensive published evidence supports the use of subcutaneously-administered apomorphine as an effec...
BackgroundSubcutaneous apomorphine infusion is a clinically established therapy for patients with Pa...
Background Subcutaneous apomorphine infusion is a clinically established therapy for patients with P...
The current pharmacotherapy of Parkinson's disease (PD) is primarily based on two classes of drugs: ...
Five patients with idiopathic Parkinson's disease with severe response fluctuations were selected fo...
Apomorphine is a dopamine agonist used in the treatment of some motor and non-motor complications du...
Apomorphine in combination with a peripheral dopamine receptor blocker (domperidone) was administere...
Continuous infusion of levodopa or apomorphine provide constant dopaminergic stimulations are good a...
The effectiveness of oral levodopa in complex Parkinson's disease (PD) is limited by its short half-...
OBJECTIVES: Despite the recent introduction of new peroral drugs as well as neurosurgical methods fo...